MedPath

erythromycin

Erythromycin Delayed-Release Capsules, USP

Approved
Approval ID

16e754a6-f8e0-4ecf-8300-c55aebe73e33

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 7, 2022

Manufacturers
FDA

Mayne Pharma Inc.

DUNS: 867220261

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

erythromycin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68308-250
Application NumberNDA050536
Product Classification
M
Marketing Category
C73605
G
Generic Name
erythromycin
Product Specifications
Route of AdministrationORAL
Effective DateDecember 7, 2022
FDA Product Classification

INGREDIENTS (6)

lactose, unspecified formInactive
Code: J2B2A4N98G
Classification: IACT
povidone, unspecifiedInactive
Code: FZ989GH94E
Classification: IACT
erythromycinActive
Quantity: 250 mg in 1 1
Code: 63937KV33D
Classification: ACTIB
FD&C Yellow NO. 6Inactive
Code: H77VEI93A8
Classification: IACT
gelatin, unspecifiedInactive
Code: 2G86QN327L
Classification: IACT
titanium dioxideInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

erythromycin - FDA Drug Approval Details